The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction

Brain

Volumn 119, Issue 4, 1996, Pages 1357-1364

  Casademont, J ^a,c   Barrientos, A ^a,b   Grau, J M ^a   Pedrol, E ^a   Estivill, X ^b   Urbano Marquez A ^a   Nunes, V ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

HIV; Mitochondrial DNA; Skeletal muscle; Zidovudine

Indexed keywords

ANTIVIRUS AGENT; CREATINE KINASE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MYOPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKELETAL MUSCLE; SOUTHERN BLOTTING; VIRUS REPLICATION;

EID: 0029745087     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.4.1357     Document Type: Article

References (38)

1. Anderson S, Bankier AT, Barrell BG, de Bruijn MHL, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290: 457-65.
2. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10.
3. Arnheim N, Cortopassi G. Deleterious mitochondrial DNA mutations accumulate in aging human tissues. [Review]. Mutat Res 1992; 275: 157-67.
4. Chalmers AC, Greco CM, Miller RG. Prognosis in AZT myopathy [see comments]. Neurology 1991; 41: 1181-4, Comment in: Neurology 1992; 42: 1252.
5. Cortopassi GA, Arnheim N. Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res 1990; 18: 6927-33.
6. Cupler EJ, Danon MJ, Jay C, Hench K, Ropka M, Dalakas MC. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol (Berl) 1995; 90: 1-6.
7. Dalakas M. HIV or zidovudine myopathy? [letter; comment]. Neurology 1994; 44: 360-1. Comment on: Neurology 1993; 43: 971-6.
8. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy [see comments]. N Engl J Med 1990; 322: 1098-105. Comment in: N Engl J Med 1990; 323: 994.
9. Gherardi R, Chariot P. HIV or zidovudine myopathy? [letter; comment]. Neurology 1994; 44: 361-2. Comment on: Neurology 1993; 43: 971-6.
10. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies [see comments]. Nature 1990; 348: 651-3. Comment in: Nature 1991; 351: 194.
11. Grau JM, Casademont J. HIV or zidovudine myopathy? [letter; comment]. Neurology 1994; 44: 361. Comment on: Neurology 1993; 43: 971-6.
12. Grau JM, Masanés F, Pedrol E, Casademont J, Fernández-Solá J, Urbano-Márquez A. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy [see comments]. Ann Neurol 1993; 34: 206-11. Comment in: Ann Neurol 1994; 35: 247-8.
13. Helbert M, Fletcher T, Peddle B, Harris JRW, Pinching AJ. Zidovudine-associated myopathy [letter]. Lancet 1988; 2: 689-90.
14. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. [Review]. N Engl J Med 1993; 328: 1686-95.
15. Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428-33.
16. Kieburtz K. HIV or zidovudine myopathy? [letter; comment]. Neurology 1994; 44: 361. Comment on: Neurology 1993; 43: 971-6.
17. Lamperth L, Dalakas MC, Dagani F, Anderson J, Ferrari R. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest 1991; 65: 742-51.
18. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991; 29: 606-14.
19. Modica-Napolitano JS. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 1993; 194: 170-7.
20. Peters BS, Winer J, Landon DN, Stotter A, Pinching AJ. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med 1993; 86: 5-15.
21. Poulton J, Sewry C, Potter C, Bougeron T, Chretien D, Wijburg F, et al. Variation in mitochondrial DNA levels in muscle from normal controls. Is depletion of mtDNA in patients with mitochondrial myopathy a distinct clinical syndrome? J Inherit Metab Dis 1995; 18: 4-20.
22. Richman DD. Antiviral therapy in HIV infection. [Review]. Annu Rev Med 1991; 42: 69-90.
23. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference [see comments]. [Review]. JAMA 1993; 270: 2583-9. Comment in: JAMA 1994; 271: 1830.
24. Sandström EG, Kaplan JC. Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. [Review]. Drugs 1987; 34: 372-90.
25. Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 1989: 244; 346-9.
26. Schröder JM, Bertram M, Schnabel R, Pfaff U. Nuclear and mitochondrial changes of muscle fibres in AIDS after treatment with high doses of zidovudine. Acta Neuropathol (Berl) 1992; 85: 39-47.
27. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II. Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest 1994a; 71: 773-81.
28. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I. L-carnitine prevents the myotoxicity of AZT in vitro. Lab Invest 1994b; 71: 102-12.
29. Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. Proc Natl Acad Sci USA 1989; 86: 7952-6.
30. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fibre disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61: 931-7.
31. Simpson MV, Chin CD, Keilbaugh SA, Lin TS, Prusoff WH. Studies on the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication. Biochem Pharmacol 1989; 38: 1033-6.
32. Simpson DM, Citak KA, Godfrey E, Godbold J, Wolfe DE. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? [see comments]. Neurology 1993; 43: 971-6. Comment in: Neurology 1994; 44: 360-4.
33. Simpson DM, Citak K, Godfrey E, Godbold J, Wolfe DE. HIV or zidovudine myopathy? [comment]. Neurology 1994; 44: 362-4. Comment on: Neurology 1994; 44: 360-1.
34. 31P in vivo magnetic resonance spectroscopy. J Clin Invest 1995; 96: 126-31.
35. Till M, MacDonell KB. Myopathy with human immunodeficiency virus type I (HIV-1) infection: HIV-1 or zidovudine? [Review]. Ann Intern Med 1990; 113: 492-4.
36. Tritschler HJ, Andreetta F, Moraes CT, Bonilla E, Arnaudo E, Danon M. et al. Mitochondrial myopathy of childhood associated with depletion of mitochondrial DNA. Neurology 1992; 42: 209-17.
37. Volverding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter [see comments]. N Engl J Med 1990; 322: 941-9. Comment in: N Engl J Med 1990; 322: 1000-2, Comment in: N Engl J Med 1990; 323: 754-6.
38. Wallace DC. Mitochondrial diseases: genotype versus phenotype. [Review]. Trends Genet 1993; 9: 128-33.